Affinités Santé, 59 Rue du Faubourg Saint-Antoine, 75011 Paris, France; Cap Evidence, 105, rue des Moines, 75017 Paris, France.
Pôle de Neurologie, Hôpital Roger-Salengro, CHRU de Lille, 2, avenue Oscar-Lambret, 59000 Lille, France.
Rev Neurol (Paris). 2018 Jan-Feb;174(1-2):28-35. doi: 10.1016/j.neurol.2017.06.016. Epub 2017 Nov 8.
Launched in the US in 2012, Choosing Wisely is a campaign promoted by the American Board of Internal Medicine (ABIM) Foundation with the goal of improving healthcare effectiveness by avoiding wasteful or unnecessary medical tests, treatments and procedures. It uses concise recommendations produced by national medical societies to start discussions between physicians and patients on the relevance of these services as part of a shared decision-making process. The Multiple Sclerosis Focus Group (Groupe de Reflexion Autour de la Sclérose en Plaques; GRESEP) undertook a pilot study to assess the relevance and feasibility of this approach in the management of multiple sclerosis (MS) in France.
Recommendations were developed using the formal consensus method from the guidelines of the French National Health Authority (HAS). A steering committee selected the themes and drafted concise evidence reviews. An independent rating group then assessed these recommendations for clarity, relevance and feasibility.
Seven recommendations were accepted: (1) avoid systematic ordering of multimodal evoked potential studies for diagnosing MS; (2) do not treat MS relapses with low-dose oral corticosteroids; (3) when treating MS relapse with high-dose corticosteroids, the systematic use of the intravenous route is unnecessary if the oral route can be used; (4) systematic hospitalization is not necessary for treating MS relapse with high-dose corticosteroid therapy, particularly if the oral route is used, except for the first treated relapse and the presence of exclusion or non-eligibility criteria; (5) in the absence of clinical signs or symptoms of urinary infection, avoid systematic screening with urine microscopy and culture before the administration of corticosteroid therapy for MS relapse in patients using intermittent self-catheterization; (6) avoid antibiotic treatment of clinically asymptomatic MS patients using intermittent self-catheterization, even if urine microscopy and culture reveal the presence of microorganisms; and (7) avoid introducing symptomatic drug treatment for MS-related fatigue.
This pilot study, the first of its kind in France, has demonstrated the relevance and feasibility of adapting the Choosing Wisely model to MS by practitioners specializing in the disorder. However, the acceptability of these recommendations by other practitioners in other specialist fields as well as their impact on everyday clinical practices now need to be studied.
“明智选择”是美国内科医师学院基金会于 2012 年在美国发起的一项活动,旨在通过避免不必要的医疗检查、治疗和程序,提高医疗保健的效果。它使用由国家医学协会制定的简明建议,在医生和患者之间就这些服务的相关性展开讨论,作为共同决策过程的一部分。多发性硬化症焦点小组(Groupe de Réflexion Autour de la Sclérose en Plaques;GRESEP)开展了一项试点研究,以评估这种方法在法国多发性硬化症(MS)管理中的相关性和可行性。
建议使用法国国家卫生管理局(HAS)指南的正式共识方法制定。指导委员会选择主题并起草简明的证据审查。然后,一个独立的评估小组评估这些建议的清晰度、相关性和可行性。
接受了 7 项建议:(1)避免为诊断 MS 而系统地进行多模态诱发电位研究;(2)不要用低剂量口服皮质类固醇治疗 MS 复发;(3)用大剂量皮质类固醇治疗 MS 复发时,如果可以使用口服途径,则无需系统使用静脉途径;(4)用大剂量皮质类固醇治疗 MS 复发时,无需系统住院治疗,除非是第一次治疗的复发且存在排除或不合格标准;(5)在使用间歇性自我导尿的 MS 复发患者中,在接受皮质类固醇治疗之前,如无尿路感染的临床症状或体征,避免用尿液显微镜检查和培养进行系统筛查;(6)在使用间歇性自我导尿的 MS 患者中,即使尿液显微镜检查和培养显示有微生物存在,也无需用抗生素治疗无症状的 MS 患者;(7)避免对 MS 相关疲劳的患者进行有症状的药物治疗。
这项试点研究是法国首例,表明通过专门从事该疾病的医生,将“明智选择”模式应用于 MS 是具有相关性和可行性的。然而,现在需要研究其他专科领域的其他医生对这些建议的接受程度以及它们对日常临床实践的影响。